Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese Mergers Provide Opening For Biotech Deals - Novartis Licensing Head

This article was originally published in PharmAsia News

Executive Summary

Recent mergers in the Japanese pharmaceutical market have provided U.S. and European biotechs enhanced opportunities to partner with Japanese pharmas looking to fill pipelines and compete globally, according to Novartis Global Head of Business Development and Licensing Anthony Rosenberg. However, Rosenberg cautioned that this same dynamic also could mean fewer opportunities for multinational pharmas to license compounds from their Japanese counterparts

You may also be interested in...

Theravance’s First NDA Is Antibiotic Telavancin

Firm is seeking approval of telavancin for complicated skin and skin structure infections caused by Gram-positive bacteria.

Novartis Shanghai R&D Center To Focus On Diseases Prevalent In China

Establishment of the R&D site reflects Novartis’ commitment to the region, according to the drug maker.

Daiichi Sankyo Gains Marketing Rights To Ajinomoto's Diabetes Drug

Phase I compound AJD101 has a new mechanism of action that stimulates insulin independent glucose uptake in preclinical studies, according to the two Tokyo-based drug makers.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts